Management of hepatitis C: current and future perspectives - PubMed (original) (raw)
Management of hepatitis C: current and future perspectives
J H Hoofnagle. J Hepatol. 1999.
Abstract
Chronic hepatitis C is now a major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. In March 1997, the National Institutes of Health sponsored a Consensus Development Conference entitled "Management of Hepatitis C". The final statement from the Consensus Panel set forth clear, evidence-based guidelines and recommendations regarding the diagnosis, evaluation, prevention and therapy of hepatitis C. The conclusions of the Consensus Panel have been widely accepted and have brought some degree of uniformity to the management of hepatitis C. An important issue is how to keep such recommendations current in such a rapidly evolving area of medicine. In the 2 years since the Consensus Conference there have been important advances in the management of chronic hepatitis C. Two recommendations of the Consensus Panel deserve modification: first, on the clinical usefulness of genotyping of hepatitis C virus and second, on the optimal therapeutic regimen. Two large multicenter, prospective controlled trials have shown that the combination of alpha interferon with ribavirin provides higher sustained virologic responses than interferon alone and that optimal therapy is a 24-week course for patients with genotypes 2 and 3 and a 48-week course for patients with genotype 1. Furthermore, therapy can be stopped at 24 weeks if HCV RNA is still present. Many clinical challenges remain. Major current needs are for accurate means of assessing the grade and stage of disease, for the likelihood of disease progression and of response to therapy as well as for viral eradication by treatment. Also important are new therapies for hepatitis C that might be used alone or in combination with interferon and ribavirin; therapies that could be applied to a wide variety of patients, with different stages of disease and with other comorbitities.
Similar articles
- NIH Consensus Statement on Management of Hepatitis C: 2002.
[No authors listed] [No authors listed] NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review. - NIH consensus development statement on management of hepatitis B.
Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Sorrell MF, Strader DB, Trotter HT. Belongia EA, et al. NIH Consens State Sci Statements. 2008 Oct 22-24;25(2):1-29. NIH Consens State Sci Statements. 2008. PMID: 18949020 - Consensus guidelines for the management of hepatitis C infection.
Consensus Guidelines Committee for the Management of Hepatitis C Infection. Consensus Guidelines Committee for the Management of Hepatitis C Infection. Saudi Med J. 2003 Jul;24 Suppl 2:S99-118. Saudi Med J. 2003. PMID: 25121186 - Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ, Perry CM. Scott LJ, et al. Drugs. 2002;62(3):507-56. doi: 10.2165/00003495-200262030-00009. Drugs. 2002. PMID: 11827565 Review. - National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C.
[No authors listed] [No authors listed] Hepatology. 1997 Sep;26(3 Suppl 1):2S-10S. doi: 10.1002/hep.510260701. Hepatology. 1997. PMID: 9305656 Review.
Cited by
- Modulation of Kinase Activities In Vitro by Hepatitis C Virus Protease NS3/NS4A Mediated-Cleavage of Key Immune Modulator Kinases.
Abdullah MAF, McWhirter SM, Suo Z. Abdullah MAF, et al. Cells. 2023 Jan 25;12(3):406. doi: 10.3390/cells12030406. Cells. 2023. PMID: 36766748 Free PMC article. - Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
van Santen DK, de Vos AS, Matser A, Willemse SB, Lindenburg K, Kretzschmar ME, Prins M, de Wit GA. van Santen DK, et al. PLoS One. 2016 Oct 6;11(10):e0163488. doi: 10.1371/journal.pone.0163488. eCollection 2016. PLoS One. 2016. PMID: 27711200 Free PMC article. - Glycosylation and liver cancer.
Mehta A, Herrera H, Block T. Mehta A, et al. Adv Cancer Res. 2015;126:257-79. doi: 10.1016/bs.acr.2014.11.005. Epub 2015 Feb 7. Adv Cancer Res. 2015. PMID: 25727150 Free PMC article. Review. - Persistent oxidative stress in patients with chronic active hepatitis-C infection after antiviral therapy failure.
El-Kannishy G, Arafa M, Abdelaal I, Elarman M, El-Mahdy R. El-Kannishy G, et al. Saudi J Gastroenterol. 2012 Nov-Dec;18(6):375-9. doi: 10.4103/1319-3767.103429. Saudi J Gastroenterol. 2012. PMID: 23150023 Free PMC article. - Examination of the activity of camel milk casein against hepatitis C virus (genotype-4a) and its apoptotic potential in hepatoma and hela cell lines.
Almahdy O, El-Fakharany EM, El-Dabaa E, Ng TB, Redwan EM. Almahdy O, et al. Hepat Mon. 2011 Sep;11(9):724-30. doi: 10.5812/kowsar.1735143X.722. Hepat Mon. 2011. PMID: 22235215 Free PMC article.